Shire acquires biopharmaceutical company SARcode
Pharmaceuticals group Shire has acquired California-based biopharmaceutical company SARcode to build its presence in the ophthalmology therapeutic market and add a dry eye treatment, Lifitegrast, to its portfolio.
Shire has revealed that it plans to file a biologics license application for its enzyme replacement therapy for Fabry disease Replagal.